IL312744A - MAGEA1 immunogenic peptides, binding proteins that recognize MAGEA1 immunogenic peptides and uses thereof - Google Patents

MAGEA1 immunogenic peptides, binding proteins that recognize MAGEA1 immunogenic peptides and uses thereof

Info

Publication number
IL312744A
IL312744A IL312744A IL31274424A IL312744A IL 312744 A IL312744 A IL 312744A IL 312744 A IL312744 A IL 312744A IL 31274424 A IL31274424 A IL 31274424A IL 312744 A IL312744 A IL 312744A
Authority
IL
Israel
Prior art keywords
magea1
immunogenic peptides
binding proteins
proteins recognizing
recognizing
Prior art date
Application number
IL312744A
Other languages
English (en)
Hebrew (he)
Original Assignee
Tscan Therapeutics Inc
Dana Farber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tscan Therapeutics Inc, Dana Farber Cancer Inst Inc filed Critical Tscan Therapeutics Inc
Publication of IL312744A publication Critical patent/IL312744A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K39/001186—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
IL312744A 2021-11-10 2022-11-10 MAGEA1 immunogenic peptides, binding proteins that recognize MAGEA1 immunogenic peptides and uses thereof IL312744A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163277924P 2021-11-10 2021-11-10
US202263317337P 2022-03-07 2022-03-07
US202263342415P 2022-05-16 2022-05-16
PCT/US2022/049556 WO2023086480A2 (en) 2021-11-10 2022-11-10 Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof

Publications (1)

Publication Number Publication Date
IL312744A true IL312744A (en) 2024-07-01

Family

ID=86336428

Family Applications (1)

Application Number Title Priority Date Filing Date
IL312744A IL312744A (en) 2021-11-10 2022-11-10 MAGEA1 immunogenic peptides, binding proteins that recognize MAGEA1 immunogenic peptides and uses thereof

Country Status (11)

Country Link
US (1) US20230270832A1 (https=)
EP (1) EP4430067A2 (https=)
JP (1) JP2024546018A (https=)
KR (1) KR20240112285A (https=)
AU (2) AU2022268347C1 (https=)
CA (1) CA3237903A1 (https=)
CO (1) CO2024007212A2 (https=)
IL (1) IL312744A (https=)
MX (1) MX2024005746A (https=)
TW (1) TW202340224A (https=)
WO (1) WO2023086480A2 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116716327B (zh) * 2023-08-04 2023-10-20 科士华(南京)生物技术有限公司 一种构建tcr载体的方法
TW202523702A (zh) * 2023-10-27 2025-06-16 美商帝斯肯醫療公司 Magea1免疫原性肽、識別magea1免疫原性肽之結合蛋白及其用途
TWI871128B (zh) * 2023-12-08 2025-01-21 陳乃銘 可準確提供循環腫瘤細胞（ｃｔｃ）所需藥物種類之方法
WO2025217037A2 (en) * 2024-04-08 2025-10-16 Tscan Therapeutics, Inc. Use of binding proteins for treatment of solid tumors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340577B2 (en) * 1992-08-07 2016-05-17 Epimmune Inc. HLA binding motifs and peptides and their uses
JPH09502086A (ja) * 1993-08-06 1997-03-04 サイテル コーポレイション 完全ｍａｇｅ１遺伝子のクローニング及び特性決定
WO2005115447A2 (en) * 2004-05-25 2005-12-08 The Trustees Of The University Of Pennsylvania Human anti-cancer immunotherapy
WO2010037395A2 (en) * 2008-10-01 2010-04-08 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
AU2017252192C1 (en) * 2016-04-19 2023-06-08 Imcyse Sa Novel immunogenic CD1d binding peptides
CN113795586B (zh) * 2019-03-25 2026-03-27 大学健康网络 T细胞受体及其使用方法
WO2021119545A1 (en) * 2019-12-11 2021-06-17 Gritstone Bio, Inc. Durable vaccination
US11464842B1 (en) * 2021-04-28 2022-10-11 Think Therapeutics, Inc. Compositions and method for optimized peptide vaccines using residue optimization

Also Published As

Publication number Publication date
MX2024005746A (es) 2024-07-19
CA3237903A1 (en) 2023-05-19
CO2024007212A2 (es) 2024-09-09
US20230270832A1 (en) 2023-08-31
AU2022268347C1 (en) 2024-04-18
EP4430067A2 (en) 2024-09-18
JP2024546018A (ja) 2024-12-17
AU2022268347A1 (en) 2023-05-25
WO2023086480A2 (en) 2023-05-19
TW202340224A (zh) 2023-10-16
WO2023086480A3 (en) 2023-06-29
AU2022268347B2 (en) 2024-01-18
KR20240112285A (ko) 2024-07-18
AU2024200495A1 (en) 2024-02-15

Similar Documents

Publication Publication Date Title
IL312744A (en) MAGEA1 immunogenic peptides, binding proteins that recognize MAGEA1 immunogenic peptides and uses thereof
AU2021311470A1 (en) Binding proteins recognizing SARS-CoV-2 antigens and uses thereof
IL307601A (en) MAGEC2 immunogenic peptides, MAGEC2 immunogenic peptide-recognizing binding proteins and uses thereof
EP4299803A3 (en) Macromolecule analysis employing nucleic acid encoding
IL307429A (en) HA-2 antigen-recognizing binding proteins and their uses
IL299907A (en) Paired peptides and their methods
EP3919507A3 (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
IL304681A (en) psma binding proteins and uses thereof
IL312043A (en) Mesothelin binding proteins and their uses
WO2020227228A3 (en) Neutralizing antibodies to plasmodium falciparum circumsporozoite protein and their use
WO2022099100A3 (en) Binding proteins recognizing ha-1 antigen and uses thereof
WO2023086477A3 (en) Binding proteins recognizing hpv16 e7 antigen and uses thereof
IL319653A (en) Immunogenic PRAME peptides, binding proteins that recognize immunogenic PRAME peptides and uses thereof
IL325709A (en) Anti-a-beta protein antibodies, methods and uses thereof
HK1249092A1 (zh) 用於样品制备尤其是用於质谱分析的方式和方法
IL319654A (en) MAGEA1 immunogenic peptides, binding proteins that recognize MAGEA1 immunogenic peptides and uses thereof
CA3307942A1 (en) Magea1 immunogenic peptides, binding proteins recognizing magea1 immunogenic peptides, and uses thereof
HK40108870A (en) Mesothelin binding proteins and uses thereof
HK40113395A (en) Antigen binding proteins and uses thereof
GB202415521D0 (en) Novel peptides,uses and methods thereof
HK40130551A (zh) 融合蛋白/肽、方法及其用途
HK40078946A (en) Interferon-associated antigen binding proteins and uses thereof
HK40111663A (en) Recombinant glycan binding proteins and its use
AU2021903864A0 (en) Improved binding proteins and uses thereof
GB202008694D0 (en) Pathogen binding polypeptides, and uses related thereto